Profound Medical Corp. The company is headquartered in Mississauga, Canada.
| Revenue (TTM) | $19.09M |
| Gross Profit (TTM) | $13.70M |
| EBITDA | $-34.88M |
| Operating Margin | -445.70% |
| Return on Equity | -73.50% |
| Return on Assets | -39.50% |
| Revenue/Share (TTM) | $0.57 |
| Book Value | $1.36 |
| Price-to-Book | 4.19 |
| Price-to-Sales (TTM) | 11.51 |
| EV/Revenue | 9.42 |
| EV/EBITDA | -5.75 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12.30% |
| Shares Outstanding | $36.53M |
| Float | $35.50M |
| % Insiders | 4.09% |
| % Institutions | 45.03% |
Volatility is currently expanding
The mean of analysts' price targets for Profound Medical (PROF) points to a 58.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO ® system.
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is pleased to announce entering into a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX) (“Telix”), a commercial-stage global radiopharmaceutical company. The agreement establishes a framework through which the companies intend to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's advanced prostate-specific membrane antigen (“PSMA”) targeting PET molecular imaging technologies, Gozellix® and Illuccix® 1, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO® platform across the prostate care continuum.
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47%
TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.
TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the appointment of Richard Fabian as its new President, effective immediately.
Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, who has stepped down as the Company's Chief Financial Officer.
A patient-centered initiative focused on education, connection, and support A patient-centered initiative focused on education, connection, and support
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PROF and any ticker you trade — then tracks every position and per-strategy win rate.
